Corneal endothelial safety following subconjunctival and intrastromal injection of bevacizumab for corneal neovascularization.

Lichtinger, Alejandro; Yeung, Sonia N; Kim, Peter; Amiran, Maoz D; Elbaz, Uri; Slomovic, Allan R

Lichtinger, Alejandro; Yeung, Sonia N; Kim, Peter; Amiran, Maoz D; Elbaz, Uri; Slomovic, Allan R.

Affiliation

Lichtinger A; Department of Ophthalmology, Toronto Western Hospital, University of Toronto, 399 Bathurst Street, East Wing 6E 401, Toronto, ON, M5T 2S8, Canada, drlichtinger@yahoo.com.

Int Ophthalmol ; 34(3): 597-601, 2014 Jun.

Article in En | MEDLINE | ID: mdl-23722674

Subject(s)

Angiogenesis Inhibitors/adverse effects; Antibodies, Monoclonal, Humanized/adverse effects; Corneal Neovascularization/drug therapy; Endothelium, Corneal/pathology; Adult; Aged; Aged, 80 and over; Analysis of Variance; Bevacizumab; Endothelial Cells/cytology; Female; Humans; Injections, Intraocular; Male; Middle Aged; Young Adult

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Endothelium, Corneal / Corneal Neovascularization / Angiogenesis Inhibitors / Antibodies, Monoclonal, Humanized Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Int Ophthalmol Year: 2014 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google